NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 34.16 P/S
- 6.40 P/B
- -0.32 EPS
- -2,078.99% Cash ROIC
- 1.62 Cash Ratio
- 0 / N/A % Dividend
- 232,977.00 Avg. Vol.
- 51.63M Shares
- 34.59M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Business Wire (press release) - Mar 26, 2015
Seeking Alpha (registration) - Mar 4, 2015
Insurance News Net - Feb 20, 2015
Seeking Alpha - Jan 7, 2015
Dakota Financial News - Mar 25, 2015
GlobeNewswire (press release) - Mar 20, 2014
Bar and Graph Report - Mar 12, 2015
Short Interest in NovaBay Pharmaceuticals Declines By 1.6% (NBY) - WKRB News
Business Wire (press release) - Mar 16, 2015
Markets Emerging - Mar 25, 2015
Seeking Alpha - Dec 9, 2013